AGXT Gene (Hyperoxaluria Type 1) Next-Generation Sequencing (NGS) Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing. Next-Generation Sequencing with comprehensive coverage of the AGXT gene.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post-test clinical guidance with board-certified medical geneticists to interpret results and discuss implications.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The AGXT Gene NGS Test screens for pathogenic variants in the AGXT gene, which cause primary hyperoxaluria type 1—a rare metabolic disorder leading to recurrent kidney stones, nephrocalcinosis, and end-stage renal disease.

Feature	Our Genetic Test (AGXT)	Standard Sanger Sequencing
Methodology	Next-Generation Sequencing (NGS) with full gene coverage	Sanger sequencing of limited exons
Sensitivity	>99.9% for SNVs, indels, and CNVs	High for targeted regions; may miss deep intronic or large deletions
Turnaround Time	3–4 weeks	6–8 weeks
Clinical Reporting	Comprehensive ACMG variant classification & genetic counseling notes	Basic variant description

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics, I emphasize that this NGS-based AGXT gene test provides definitive molecular diagnosis for primary hyperoxaluria type 1. However, results must be interpreted within the full clinical context and family history. A positive mutation confirms the diagnosis and requires multidisciplinary management to prevent irreversible kidney damage.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Medication Considerations

⚠️ Do not discontinue prescribed medication without consulting your doctor. Pyridoxine (vitamin B6) therapy is often initiated under strict medical supervision for certain genotypes. Always follow your specialist’s guidance.

Patient Safety & Exclusion Criteria

Exclusion Criteria: Known active bleeding disorder or severe thrombocytopenia requiring medical clearance prior to venipuncture.
Emergency Red Flags: If you experience severe flank pain, inability to urinate, or gross hematuria, seek immediate emergency care regardless of scheduled testing.
Pediatric Consent: For minors, a legal guardian must provide written informed consent during sample collection in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.

Patient FAQ & Clinical Guidance

1. What is the purpose of the AGXT gene test and who should consider it?

This test detects mutations in the AGXT gene to confirm primary hyperoxaluria type 1 in individuals with recurrent calcium oxalate kidney stones, unexplained nephrocalcinosis, or a family history of the disease. It is also used for carrier screening in at-risk populations.

2. How is the sample collected and what is the turnaround time?

A simple peripheral whole blood draw is performed by our DHA-licensed phlebotomists during a scheduled home visit. Results are delivered in 3 to 4 weeks via a secure online portal and accompanied by a telephonic genetic counseling session.

3. Is this test covered by UAE health insurance and what are the next steps if positive?

We verify insurance pre-authorization directly via WhatsApp. A positive result prompts an immediate teleconsultation with a clinical geneticist and a referral to a nephrologist for lifelong management and potential pyridoxine therapy evaluation.

UAE Regulatory & Data Privacy Adherence

All services comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. The laboratory is accredited under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License 1143. Corporate lab: DNA Labs UAE, located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.

Clinical & Logistical Metadata

Test Name	AGXT Gene (Hyperoxaluria Type 1) Next-Generation Sequencing (NGS) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 weeks
Sample Type / Matrix	Peripheral whole blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection)
Methodology Used	Next-Generation Sequencing (NGS)
ICD-10-CM Code	E74.8, Z15.02, Z14.8
LOINC Code	82931-7
DHA Facility License & Address	DHA License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE